Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    ... in MDS. The two hypomethylating agents, 5-azacytidine ( azacitidine ) and 5-aza-2-deoxycytidine ( decitabine ), are both ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Current and future management options for myelodysplastic syndromes.

    ... of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these developments, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... with higher-risk MDS include hypomethylating agents ( azacitidine and decitabine ), intensive chemotherapy (ICT), ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Myelodysplastic syndromes in older adults.

    ... the drugs lenalidomide , decitabine , and azacitidine have offered treatment options to patients ineligible for ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... such as decitabine (5-aza-deoxycytidine) and 5- azacitidine , have led to the expansion of the therapeutic arsenal for MDS. ... and head-to-head comparison studies of decitabine and 5-azacitidine will provide valuable pre-clinical and clinical data, enhancing ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... Drug Administration-approved for treatment of MDS: (1) azacitidine , (2) decitabine , and (3) lenalidomide . ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... therapies include the DNA methyltransferase inhibitors azacitidine and decitabine . Recently, azacitidine demonstrated the ability to extend survival by as much as 74% ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Myelodysplastic syndromes: What do hospitalists need to know?

    ... prediction and risk-adapted therapy. The addition of azacitidine , decitabine , and lenalidomide to ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. An update on the treatment of myelodysplastic syndromes.

    ... with del(5q), and two different hypomethylating agents, azacitidine and decitabine , are approved for intermediate-2- and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.

    ... Among high and very-high IPSS-R patients receiving azacitidine , OS was significantly improved versus patients not receiving azacitidine, with corresponding median OS of 25 versus 18 months (P=0.023) and ...

    Research Article last updated 07/20/2018 - 5:15pm.